OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), multi-modality specialty pharma pure-play CDMO, and Xbrane Biopharma AB (Nasdaq ticker XBRANE), a Sweden-headquartered biotechnology company, today announced a strategic partnership focused on the commercial manufacturing of Xbrane’s biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting